Moebius Medical ⚠ Under review

About

Funding history · 1 round · — total

Headcount over time

Q&A

What is Moebius Medical's primary focus?

Moebius Medical is a clinical-stage biotechnology company focused on developing novel pain relief treatments for osteoarthritis (OA), utilizing proprietary liposomal technologies.

What is Moebius Medical's lead product?

Moebius Medical's lead product is MM-II, an intra-articular injection for treating pain in knee OA, which is currently in Phase 3 clinical development.

When was Moebius Medical founded and what was its initial purpose?

Moebius Medical was founded in 2008 within the RAD Biomed Accelerator to commercialize innovative patented lipid-based technologies licensed from Yissum, T3, and Hadasit.

What was the total amount raised by Moebius Medical?

Moebius Medical has raised a total of $7,000,000 USD.

When did Moebius Medical secure its last known funding round?

Moebius Medical secured a Seed round in June 2014, raising $7,000,000 USD.

What is the current employee count for Moebius Medical?

Moebius Medical has an employee count in the 1-10 range.

What significant partnership did Moebius Medical enter into for MM-II?

In December 2016, Moebius Medical and Sun Pharma entered into an exclusive worldwide licensing deal for the further development of MM-II.

When did Moebius Medical receive FDA clearance for its MM-II clinical trial?

In December 2020, the FDA cleared Moebius Medical's Investigational New Drug application to initiate a global multi-center Phase IIb clinical trial of MM-II.

What recent regulatory designation did MM-II receive?

In September 2024, Sun Pharma and Moebius Medical announced that MM-II was granted Fast Track designation for the treatment of osteoarthritis knee pain.

Team · 3

Prof. Yechezkel Barenholz

Founder · Co-inventor & Board Member

Prof. Izhak Etsion

Founder · Co-inventor

Prof. Dorit Nitzan

Founder · Co-inventor

Sectors & technology

Highlights

Tags